Platelet TGF-β1 contributions to plasma TGF-β1, cardiac fibrosis, and systolic dysfunction in a mouse model of pressure overload

Blood

Volumn 119, Issue 4, 2012, Pages 1064-1074

  Meyer, Alexander ^a   Wang, Wei ^a   Qu, Jiaxiang ^b   Croft, Lori ^c   Degen, Jay L ^d   Coller, Barry S ^a   Ahamed, Jasimuddin ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTAGLANDIN E1; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; HEART MUSCLE FIBROSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SYSTOLIC DYSFUNCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION;

EID: 84863049833     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-09-377648     Document Type: Article

References (52)

1. Christ M, Cartney-Francis NL, Kulkarni AB, et al. Immune dysregulation in TGF-beta 1-deficient mice. J Immunol. 1994;153(5):1936-1946.
2. Werner S, Krieg T, Smola H. Keratinocyte-fibroblast interactions in wound healing. J Invest Dermatol. 2007;127(5):998-1008. (Pubitemid 46625161)
3. Yang EY, Moses HL. Transforming growth factor beta 1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J Cell Biol. 1990;111(2):731-741.
4. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med. 2000;342(18):1350-1358. (Pubitemid 30408720)
5. Wang XL, Liu SX, Wilcken DE. Circulating transforming growth factor beta 1 and coronary artery disease. Cardiovasc Res. 1997;34(2):404-410. (Pubitemid 27241586)
6. Villar AV, Cobo M, Llano M, et al. Plasma levels of transforming growth factor-beta1 reflect left ventricular remodeling in aortic stenosis. PLoS One. 2009;4(12):e8476.
7. Matt P, Schoenhoff F, Habashi J, et al. Circulating transforming growth factor-beta in Marfan syndrome. Circulation. 2009;120(6):526-532.
8. Kunz D, Luley C, Heim MU, Bock M. Transforming growth factor beta is increased in plasma of patients with hematologic malignancies after transfusion of platelet concentrates. Transfusion. 1998;38(2):156-159. (Pubitemid 28145081)
9. Grainger DJ, Mosedale DE, Metcalfe JC. TGF-beta in blood: a complex problem. Cytokine Growth Factor Rev. 2000;11(1):133-145.
10. Ahamed J, Burg N, Yoshinaga K, et al. In vitro and in vivo evidence for shear-induced activation of latent transforming growth factor-beta1. Blood. 2008;112(9):3650-3660.
11. Assoian RK, Komoriya A, Meyers CA, Miller DM, Sporn MB. Transforming growth factor-beta in human platelets: identification of a major storage site, purification, and characterization. J Biol Chem. 1983;258(11):7155-7160. (Pubitemid 13059967)
12. Hu P, Zhang D, Swenson L, et al. Minimally invasive aortic banding in mice: effects of altered cardiomyocyte insulin signaling during pressure overload. Am J Physiol Heart Circ Physiol. 2003; 285(3):H1261-H1269. (Pubitemid 37048185)
13. Qu J, Volpicelli FM, Garcia LI, et al. Gap junction remodeling and spironolactone-dependent reverse remodeling in the hypertrophied heart. Circ Res. 2009;104(3):365-371.
14. Rockman HA, Wachhorst SP, Mao L, Ross J Jr. ANG II receptor blockade prevents ventricular hypertrophy and ANF gene expression with pressure overload in mice. Am J Physiol. 1994; 266(6):H2468-H2475.
15. Lengweiler S, Smyth SS, Jirouskova M, et al. Preparation of monoclonal antibodies to murine platelet glycoprotein IIb/IIIa (alphaIIbbeta3) and other proteins from hamster-mouse interspecies hybridomas. Biochem Biophys Res Commun. 1999;262(1):167-173. (Pubitemid 29412642)
16. Azhar M, Yin M, Bommireddy R, et al. Generation of mice with a conditional allele for transforming growth factor beta 1 gene. Genesis. 2009;47(6): 423-431.
17. Tiedt R, Schomber T, Hao-Shen H, Skoda RC. Pf4-Cre transgenic mice allow the generation of lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo. Blood. 2007;109(4):1503-1506. (Pubitemid 46239582)
18. Shet AS, Hoffmann TJ, Jirouskova M, et al. Morphological and functional platelet abnormalities in Berkeley sickle cell mice. Blood Cells Mol Dis. 2008;41(1):109-118.
19. Ahamed J, Janczak CA, Wittkowski KM, Coller BS. In vitro and in vivo evidence that thrombospondin-1 (TSP-1) contributes to stirring-and shear-dependent activation of platelet-derived TGF-beta1. PLoS One. 2009;4(8):e6608.
20. Abe M, Harpel JG, Metz CN, et al. An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal Biochem. 1994;216(2):276-284. (Pubitemid 24076008)
21. Broberg CS, Pantely GA, Barber BJ, et al. Validation of the myocardial performance index by echocardiography in mice: a noninvasive measure of left ventricular function. J Am Soc Echocardiogr. 2003;16(8):814-823. (Pubitemid 37391008)
22. Syed F, Diwan A, Hahn HS. Murine echocardiography: a practical approach for phenotyping genetically manipulated and surgically modeled mice. J Am Soc Echocardiogr. 2005;18(9):982- 990.
23. Cherin E, Williams R, Needles A, et al. Ultrahigh frame rate retrospective ultrasound microimaging and blood flow visualization in mice in vivo. Ultrasound Med Biol. 2006;32(5):683-691.
24. Nakamura A, Rokosh DG, Paccanaro M, et al. LV systolic performance improves with development of hypertrophy after transverse aortic constriction in mice. Am J Physiol Heart Circ Physiol. 2001; 281(3):H1104-H1112.
25. Stypmann J. Doppler ultrasound in mice. Echocardiography. 2007;24(1):97-112. (Pubitemid 46044655)
26. Yuan L, Wang T, Liu F, Cohen ED, Patel VV. An evaluation of transmitral and pulmonary venous Doppler indices for assessing murine left ventricular diastolic function. J Am Soc Echocardiogr. 2010;23(8):887-897.
27. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation; 2011.
28. Wickham H. ggplot2: elegant graphics for data analysis. New York, NY: Springer; 2009.
29. Kulkarni AB, Huh CG, Becker D, et al. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A. 1993; 90(2):770-774. (Pubitemid 23028947)
30. Shull MM, Ormsby I, Kier AB, et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature. 1992;359(6397):693-699.
31. Kuwahara F, Kai H, Tokuda K, et al. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation. 2002; 106(1):130-135. (Pubitemid 34747453)
32. Lijnen P, Petrov V, Rumilla K, Fagard R. Transforming growth factor-beta 1 promotes contraction of collagen gel by cardiac fibroblasts through their differentiation into myofibroblasts. Methods Find Exp Clin Pharmacol. 2003;25(2):79-86. (Pubitemid 36406966)
33. Shi Y, O'Brien JE Jr, Mannion JD, et al. Remodeling of autologous saphenous vein grafts: the role of perivascular myofibroblasts. Circulation. 1997; 95(12):2684-2693. (Pubitemid 27255498)
34. Abdelouahed M, Ludlow A, Brunner G, Lawler J. Activation of platelet-transforming growth factor beta-1 in the absence of thrombospondin-1. J Biol Chem. 2000;275(24):17933-17936. (Pubitemid 30414736)
35. Evrard S, Bluteau O, Tulliez M, et al. Thrombospondin- 1 is not the major activator of TGF-beta1 in thrombopoietin-induced myelofibrosis. Blood. 2011;117(1):246-249.
36. Beppu T, Gil-Bernabe P, Boveda-Ruiz D, et al. High incidence of tumors in diabetic thrombin activatable fibrinolysis inhibitor and apolipoprotein E double-deficient mice. J Thromb Haemost. 2010; 8(11):2514-2522.
37. Sanderson N, Factor V, Nagy P, et al. Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci U S A. 1995;92(7): 2572-2576.
38. Kanzler S, Lohse AW, Keil A, et al. TGF-beta1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis. Am J Physiol. 1999;276(4):G1059-G1068. (Pubitemid 29214121)
39. Buday A, Orsy P, Godo M, et al. Elevated systemic TGF-beta impairs aortic vasomotor function through activation of NADPH oxidase-driven superoxide production and leads to hypertension, myocardial remodeling, and increased plaque formation in apoE(-/-) mice. Am J Physiol Heart Circ Physiol. 2010;299(2):H386-H395.
40. Frutkin AD, Otsuka G, Stempien-Otero A, et al. TGF-[beta]1 limits plaque growth, stabilizes plaque structure, and prevents aortic dilation in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol. 2009;29(9):1251-1257.
41. Fujimi S, MacConmara MP, Maung AA, et al. Platelet depletion in mice increases mortality after thermal injury. Blood. 2006;107(11):4399-4406. (Pubitemid 43801366)
42. Huang XR, Chung AC, Zhou L, Wang XJ, Lan HY. Latent TGF-beta1 protects against crescentic glomerulonephritis. J Am Soc Nephrol. 2008;19(2): 233-242. (Pubitemid 351240645)
43. Kopp JB, Factor VM, Mozes M, et al. Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab Invest. 1996;74(6):991-1003. (Pubitemid 26182412)
44. Wakefield LM, Winokur TS, Hollands RS, Christopherson K, Levinson AD, Sporn MB. Recombinant latent transforming growth factor beta 1 has a longer plasma half-life in rats than active transforming growth factor beta 1, and a different tissue distribution. J Clin Invest. 1992;86(6):1976- 1984.
45. Kainulainen K, Pulkkinen L, Savolainen A, Kaitila I, Peltonen L. Location on chromosome 15 of the gene defect causing Marfan syndrome. N Engl J Med. 1990;323(14):935-939. (Pubitemid 20332332)
46. Kainulainen K, Sakai LY, Child A, et al. Two mutations in Marfan syndrome resulting in truncated fibrillin polypeptides. Proc Natl Acad Sci U S A. 1992;89(13):5917-5921.
47. Kainulainen K, Karttunen L, Puhakka L, Sakai L, Peltonen L. Mutations in the fibrillin gene responsible for dominant ectopia lentis and neonatal Marfan syndrome. Nat Genet. 1994;6(1):64-69. (Pubitemid 24191915)
48. Bogatkevich GS, Tourkina E, Silver RM, Ludwicka-Bradley A. Thrombin differentiates normal lung fibroblasts to a myofibroblast phenotype via the proteolytically activated receptor-1 and a protein kinase C-dependent pathway. J Biol Chem. 2001;276(48):45184-45192.
49. Gallucci RM, Lee EG, Tomasek JJ. IL-6 modulates alpha-smooth muscle actin expression in dermal fibroblasts from IL-6-deficient mice. J Invest Dermatol. 2006;126(3):561-568. (Pubitemid 43255642)
50. Yin Z, Tong Y, Zhu H, Watsky MA. ClC-3 is required for LPA-activated Cl- current activity and fibroblast-to-myofibroblast differentiation. Am J Physiol Cell Physiol. 2008;294(2):C535-C542. (Pubitemid 351264403)
51. Bishop JE. Regulation of cardiovascular collagen deposition by mechanical forces. Mol Med Today. 1998;4(2):69-75. (Pubitemid 28139144)
52. Labella M, Bengum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-messenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20(5):576-590.